Financial publications

 

The financial publications section contains the Company’s annual and quarterly reports, corporate presentations held at Investor Relations events as well as the Company’s financial guidance and financial key figures. Further information regarding the Company’s business model and its business segments can be found in the 'About' section of this website.

 

Financial Reports

Please find below Evotec's financial reports from 1999 onwards as well as respective corresponding documents such as corporate news and analyst presentations.

 

Financial Reports Archive

2023

Webcast Analyst Call Business Update Half-year 2023 (28 July 2023)

Quarterly Statement Q1

2022

Annual Report 2022

Sustainability Report 2022

Financial Statements 2022

Preliminary FY 2022 Results

Interim Statement 9M 2022

Interim Statement Q1 2022

2021

Sustainability Report

Financial Statements

Half-year Report

2020

Annual Report

Sustainability Report

Financial Statements

2019

Financial Statements

Separate non-financial group report

Webcast/Conference call regarding the acquisition of Just.Bio

2018

Annual Report

Financial Statements

Separate non-financial group report

Webcast/Conference call regarding the fiscal year 2018 results

2017

Annual Report

Financial Statements

Separate non-financial group report

Webcast/Conference call regarding the fiscal year 2017 results

Conference Call/Webcast regarding the acquisition of Aptuit

2016

Financial Statements

Conference Call/Webcast regarding strategic collaboration with Celgene

Conference Call/Webcast regarding the offer to acquire Cyprotex

2014

Financial Statements

Conference Call/Webcast announcing negotiations on major collaboration with Sanofi

2011

Annual Report

Financial Statements

Conference call Webcast announcing licence argeement with Roche

Conference call and Webcast announcing the acquisition of Compound Focus, Inc.

Conference call and Webcast announcing the acquisition of Kinaxo

2010

Financial Statements

Conference call and Webcast announcing the alliance with MedImmune

Third Quarter Report

Half Year Report

Conference call and Webcast announcing the acquisition of DeveloGen

First Quarter Report

2009

Financial Statements

Third Quarter Report

Half Year Report

First Quarter Report

2008

Financial Statements

Third Quarter Report

Half Year Report

First Quarter Report

2007

Annual Report

Financial Statements

Third Quarter Report

Half Year Report

First Quarter Report

2006

Annual Report

Financial Statements According to HGB

Third Quarter Report

Second Quarter Report

First Quarter Report

2005

Annual Report

Third Quarter Report

Second Quarter Report

First Quarter Report

New Segmental P&L Statements

2004

Third Quarter Report

Second Quarter Report

First Quarter Report

2003

Annual Report

Third Quarter Report

Second Quarter Report

First Quarter Report

2002

Annual Report

Third Quarter Report

Second Quarter Report

First Quarter Report

2001

Annual Report

Third Quarter Report

Second Quarter Report

First Quarter Report

2000

Annual Report

Third Quarter Report

Second Quarter Report

First Quarter Report

Oxford Asymmetry International plc 2000 Interim Statement

Oxford Asymmetry International plc 2000 Interim Statement

1999

Annual Report

Third Quarter Report

Oxford Asymmetry International plc Annual Report 1999

Guidance 2021

Guidance 2021
Actual 2020
Group revenues from contracts with customers 
€ 550-570 m1)
€ 500.9 m
Unpartnered R&D expenses
€ 50-60 m 
€ 46.4 m
Adjusted Group EBITDA3) 

€ 105-120 m2)

€ 123.1 m
Group revenues from contracts with customers   
Guidance 2021 € 550-570 m1)
Actual 2020 € 500.9 m
Unpartnered R&D expenses  
Guidance 2021 € 50-60 m 
Actual 2020 € 46.4 m
Adjusted Group EBITDA3)   
Guidance 2021

€ 105-120 m2)

Actual 2020 € 123.1 m

1) At unchanged exchange rates against the average rate for 2020, this forecast range would be approximately € 565 m to € 585 m, ceteris paribus.

2) At unchanged exchange rates against the average rate for 2020, this forecast range would be around € 115 m to € 130 m, ceteris paribus.

3) EBITDA is defined as earnings before interest, taxes, depreciation and amortisation of intangibles. Adjusted EBITDA excludes impairments on goodwill, other intangible and tangible assets, changes in contingent considerations as well as the total non-operating result

Financial key figures H1 2021 

H1 2021
H1 2020
H1 21|20 in %
Results:
Revenues from contracts with customers
T€
271,302
230,989
17
R&D expenses
T€
(35,434)
(29,796)
19
Operating result
T€
8,315
18,917
(56)
Adjusted Group EBITDA1)
T€
36,188
47,268
(23)
Net income
T€
112,717
7,259
>100
Balance sheet data:
Total stockholders' equity
T€
852,574
722,846
18
Capital expenditure2)
T€
(54,293)
(28,715)
(89)
Liquidity3)
T€
449,335
481,930
7
Balance sheet total
T€
1,621,116
1,462,895
11
Operating cash flow
T€
41,105
(6,971)
>100
Personnel data:
Employees as of 30 June
3,914
3,278
19
Per share:
Result (basic/diluted)
0.69/0.69
0.05/0.05
>100
Results:  
H1 2021
H1 2020
H1 21|20 in %
Revenues from contracts with customers  
T€
H1 2021 271,302
H1 2020 230,989
H1 21|20 in % 17
R&D expenses  
T€
H1 2021 (35,434)
H1 2020 (29,796)
H1 21|20 in % 19
Operating result  
T€
H1 2021 8,315
H1 2020 18,917
H1 21|20 in % (56)
Adjusted Group EBITDA1)  
T€
H1 2021 36,188
H1 2020 47,268
H1 21|20 in % (23)
Net income  
T€
H1 2021 112,717
H1 2020 7,259
H1 21|20 in % >100
 
H1 2021
H1 2020
H1 21|20 in %
Balance sheet data:  
H1 2021
H1 2020
H1 21|20 in %
Total stockholders' equity  
T€
H1 2021 852,574
H1 2020 722,846
H1 21|20 in % 18
Capital expenditure2)  
T€
H1 2021 (54,293)
H1 2020 (28,715)
H1 21|20 in % (89)
Liquidity3)  
T€
H1 2021 449,335
H1 2020 481,930
H1 21|20 in % 7
Balance sheet total  
T€
H1 2021 1,621,116
H1 2020 1,462,895
H1 21|20 in % 11
Operating cash flow  
T€
H1 2021 41,105
H1 2020 (6,971)
H1 21|20 in % >100
 
H1 2021
H1 2020
H1 21|20 in %
Personnel data:  
H1 2021
H1 2020
H1 21|20 in %
Employees as of 30 June  
H1 2021 3,914
H1 2020 3,278
H1 21|20 in % 19
 
H1 2021
H1 2020
H1 21|20 in %
Per share:  
H1 2021
H1 2020
H1 21|20 in %
Result (basic/diluted)  
H1 2021 0.69/0.69
H1 2020 0.05/0.05
H1 21|20 in % >100

Financial key figures 2020 according to IFRS

2020
2019
20|19 in %
Results:
Revenues from contracts with customers
T€
500,925
446,437
12
R&D expenses
T€
(63,945)
(58,432)
9
Operating result
T€
48,523
62,594
(23)
Adjusted Group EBITDA1)
T€
106,621
123,143
(13)
Net income
T€
6,252
37,228
(83)
Balance sheet data:
Total stockholders' equity
T€
722,846
477,029
52
Capital expenditure2)
T€
99,072
31,322
>100
Liquidity3)
T€
481,930
320,022
51
Balance sheet total
T€
1,462,895
1,180,912
24
Operating cash flow
T€
44,721
42,216
6
Personnel data:
Employees as of 31 December
3,572
3,030
18
Per share:
Result (basic/diluted)
0.04/0.04
0.25/0.25
(84)/(84)
Results:  
2020
2019
20|19 in %
Revenues from contracts with customers  
T€
2020 500,925
2019 446,437
20|19 in % 12
R&D expenses  
T€
2020 (63,945)
2019 (58,432)
20|19 in % 9
Operating result  
T€
2020 48,523
2019 62,594
20|19 in % (23)
Adjusted Group EBITDA1)  
T€
2020 106,621
2019 123,143
20|19 in % (13)
Net income  
T€
2020 6,252
2019 37,228
20|19 in % (83)
 
2020
2019
20|19 in %
Balance sheet data:  
2020
2019
20|19 in %
Total stockholders' equity  
T€
2020 722,846
2019 477,029
20|19 in % 52
Capital expenditure2)  
T€
2020 99,072
2019 31,322
20|19 in % >100
Liquidity3)  
T€
2020 481,930
2019 320,022
20|19 in % 51
Balance sheet total  
T€
2020 1,462,895
2019 1,180,912
20|19 in % 24
Operating cash flow  
T€
2020 44,721
2019 42,216
20|19 in % 6
 
2020
2019
20|19 in %
Personnel data:  
2020
2019
20|19 in %
Employees as of 31 December  
2020 3,572
2019 3,030
20|19 in % 18
 
2020
2019
20|19 in %
Per share:  
2020
2019
20|19 in %
Result (basic/diluted)  
2020 0.04/0.04
2019 0.25/0.25
20|19 in % (84)/(84)

1) Before contingent considerations and excluding impairments on goodwill, other intangible and tangible assets as well as the total non-operating result

2) Cash-relevant purchase of tangible and intangible assets

3) Cash and cash equivalents and investments

 

 

Investor Presentations

Please find below various presentations held at investor conferences or during investor calls available for your download.

Contact us

Gabriele Hansen

SVP, Head of Global Corporate Communications

T +49 160 7164389 F +49 40 560 81 333 vCard

Volker Braun

SVP, Head of Global Investor Relations & ESG

T +49 151 19405058 vCard

Anja Ben Lekhal

Investor Relations Advisor

T +49 151 51871069 vCard

Anika Meier

Investor Relations Manager

T +49 151 58358172 vCard
TOP